Gear Up for Regeneron (REGN) Q4 Earnings: Wall Street Estimates for Key Metrics
The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $10.48 per share, indicating a decline of 16.6% compared to the year-ago period. Analysts forecast revenues of $3.26 billion, representing a decrease of 4.7% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Regeneron metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Net product sales' will reach $1.82 billion. The estimate indicates a year-over-year change of +7%.
Based on the collective assessment of analysts, 'Revenues- Collaboration' should arrive at $1.35 billion. The estimate indicates a year-over-year change of -15%.
The collective assessment of analysts points to an estimated 'Revenues- Other Revenue' of $122.32 million. The estimate indicates a change of -4.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Dupixent (dupilumab)- Total' should come in at $3.13 billion. The estimate indicates a year-over-year change of +27.8%.
The average prediction of analysts places 'Revenues- Eylea (Aflibercept)- US' at $1.45 billion. The estimate indicates a change of -3.1% from the prior-year quarter.
The consensus estimate for 'Revenues- Praluent (alirocumab)- US' stands at $41.83 million. The estimate suggests a change of +17.8% year over year.
Analysts expect 'Revenues- Kevzara (sarilumab)- ROW' to come in at $40.80 million. The estimate points to a change of +17.9% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Dupixent (dupilumab)- US' will reach $2.43 billion. The estimate indicates a year-over-year change of +25.5%.
Analysts' assessment points toward 'Revenues- Eylea (Aflibercept)- ROW' reaching $871.52 million. The estimate indicates a year-over-year change of +3.9%.
The combined assessment of analysts suggests that 'Revenues- Libtayo- US' will likely reach $163.07 million. The estimate indicates a year-over-year change of +48.2%.
Analysts forecast 'Revenues- Libtayo- ROW' to reach $88.94 million. The estimate indicates a change of +51.3% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Evkeeza- US' will reach $18.90 million. The estimate indicates a change of +26% from the prior-year quarter.
View all Key Company Metrics for Regeneron here>>>
Over the past month, Regeneron shares have recorded returns of +8.8% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #1 (Strong Buy), REGN will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
